ArticleScience China. Life sciences2026
Cell type-specific contribution of low-density lipoprotein receptor to atherosclerosis.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated blood low-density lipoprotein (LDL) levels are a major risk factor for cardiovascular disease. Increasing LDL receptor (LDLR) expression effectively reduces blood LDL and serves as a key therapeutic strategy for preventing and treating cardiovascular disease. However, it remains unclear how LDLR in different aortic cells contributes to atherosclerosis progression. In this study, we found that hepatocyte-specific deletion of Ldlr in combination with high-fat, high-cholesterol diet feeding induced hypercholesterolemia and atherosclerosis in mice. On this background, further deletion of Ldlr in endothelial cells or smooth muscle cells had no significant effects on atherosclerosis, whereas myeloid-selective ablation of Ldlr markedly attenuated atherosclerotic plaque formation. The decreased percentages of T cells and natural killer T cells in the aorta of mice lacking Ldlr in myeloid cells partially explained the reduced atherosclerotic burden, despite that bone marrow-derived macrophages from Ldlr knockout mice could still be induced to form foam cells in vitro. Therefore, LDLR is better to be elevated in a cell-specific manner for cardiovascular disease prevention and treatment.
Indexed as
Identifiers
41587010What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.